Patents Examined by Mindy Newman
-
Patent number: 9017673Abstract: The object of the present invention is analogues of peptides or parent proteins, these peptide analogues, comprising at least one aza-?3 aminoacyl residue, and also their uses in pharmaceutical compositions or for the diagnosis of pathologies wherein the aforesaid peptides or parent proteins are involved.Type: GrantFiled: June 11, 2004Date of Patent: April 28, 2015Assignee: Centre National de la Recherche ScientifiqueInventors: Michèle Floc'h Baudy, Olivier Busnel, Sylviane Muller
-
Patent number: 8993514Abstract: Methods of using portions of the N-terminal domain of prion protein for binding hemin are disclosed. In a particular embodiment, a method comprises administering at least one isolated amino acid sequence comprising a peptide from the octarepeat region of PrPC to a solution containing hemin, wherein the isolated amino acid sequence is effective for forming one or more chemical bonds with hemin.Type: GrantFiled: July 8, 2013Date of Patent: March 31, 2015Assignee: Florida State University Research Foundation, Inc.Inventor: Ewa Bienkiewicz
-
Patent number: 8980874Abstract: Methods of treating diabetic ketoacidosis are disclosed. The methods utilize an endothelin antagonist to treat diabetic ketoacidosis in mammals, including humans.Type: GrantFiled: April 30, 2010Date of Patent: March 17, 2015Assignee: Midwestern UniversityInventor: Anil Gulati
-
Patent number: 8962559Abstract: The present invention relates to pharmaceutical compositions for the controlled and sustained release of active substance comprising a biodegradable polymer or copolymer. Furthermore, the invention relates to pharmaceutical compositions for the controlled and sustained release of at least one active substance such as peptides or hormones and analogs thereof and the manufacturing process of such pharmaceutical compositions.Type: GrantFiled: April 29, 2010Date of Patent: February 24, 2015Assignee: Ipsen Pharma S.A.S.Inventors: Roland Cherif-Cheikh, Fédéric Lacombe, Maria-Luisa Torres Salgado, Perrine Cambriel, Mercé Cardus Malaspina, Isabel Diaz Del Consuelo, Martin Montes, Fabien Jeannerot, Marie Delporte, Anne Brochard, Joël Richard
-
Patent number: 8961929Abstract: It is an object of the present invention to provide a targeting agent, which enables the delivery of a drug to tumor sites or the imaging of tumor sites by utilizing its effect of accumulating to such tumor sites. The present invention provides a targeting agent for tumor site, which comprises a hydrophilic polymer-modified carrier coated with a gelatin-like protein that has repeats of a sequence represented by Gly-X-Y characteristic to collagen and has two or more sequences of cell adhesion signals in a single molecule wherein X and Y each independently represent an amino acid and a plurality of Gly-X-Y sequences may be the same or different.Type: GrantFiled: January 7, 2011Date of Patent: February 24, 2015Assignee: FUJIFILM CorporationInventors: Kazutaka Ogiwara, Makoto Ohno, Masayoshi Kojima, Masayuki Kawakami, Chihaya Kakinuma, Tasuku Sasaki, Kiyohito Takada
-
Patent number: 8951974Abstract: Provide are a peptide gel with practically sufficient mechanical strength and a self-assembling peptide capable of forming the peptide gel. The self-assembling peptide is formed of the following amino acid sequence: a1b1c1b2a2b3 db4a3b5c2b6a4 where: a1 to a4 each represent a basic amino acid residue; b1 to b6 each represent an uncharged polar amino acid residue and/or a hydrophobic amino acid residue, provided that at least five thereof each represent a hydrophobic amino acid residue; c1 and c2 each represent an acidic amino acid residue; and d represents a hydrophobic amino acid residue.Type: GrantFiled: March 26, 2014Date of Patent: February 10, 2015Assignees: Menicon Co., Ltd., National University Corporation Okayama UniversityInventors: Yusuke Nagai, Hidenori Yokoi, Koji Uesugi, Keiji Naruse
-
Patent number: 8940501Abstract: The present invention relates to methods for ligation. The invention provides novel reagents and methods for ligating an acyl donor compound with an acyl acceptor compound. Provided acyl donor compounds comprise a transamidase recognition sequence that allows ligation with a nucleophilic acyl acceptor in the presence of transamidase. The invention further provides kits comprising acyl donor compounds and optionally comprising other reagents for ligation.Type: GrantFiled: February 1, 2010Date of Patent: January 27, 2015Assignee: Whitehead Institute for Biomedical ResearchInventors: Hidde L. Ploegh, John M. Antos, Maximilian Wei-Lin Popp, Carla Guimaraes
-
Patent number: 8937039Abstract: The present invention provides peptide-based peroxidase inhibitors having the formula AA1-AA2-AA3, wherein AA1 is a positively charged, negatively charged or neutral amino acid, AA2 is a redox active amino acid, and AA3 is an amino acid possessing a reducing potential such that AA3 is capable of undergoing a redox reaction with a radical of amino acid AA2 or a retro or retro-inverso analog thereof. The result of such a combination is a highly effective inhibitor of peroxidase activity that has potent anti-inflammatory properties in widely diverse models of vascular disease and injury. Exemplary tripeptides effectively inhibit peroxidase mediated LDL oxidation, increase vasodilation in SCD mice, inhibit eosinophil infiltration and collagen deposition in asthma mice, inhibit acute lung injury, and decrease ischemic injury of the heart.Type: GrantFiled: November 15, 2013Date of Patent: January 20, 2015Assignee: The Medical College of Wisconsin, Inc.Inventors: Hao Zhang, Yang Shi, Hao Xu, Kirkwood A. Pritchard, Jr.
-
Patent number: 8921307Abstract: The invention provides a synthetic polypeptide of Formula I? (SEQ ID NO: 1): X1-X2-X3-R—X5-X6-X7-X8-X9-X10-X11-X12-X13??I or an amide, an ester or a salt thereof, wherein X1, X2, X3, X5, X6, X7, X8, X9, X10, X11, X12 and X13 are defined herein. The polypeptides are agonist of the APJ receptor. The invention also relates to a method for manufacturing the polypeptides of the invention, and its therapeutic uses such as treatment or prevention of acute decompensated heart failure (ADHF), chronic heart failure, pulmonary hypertension, atrial fibrillation, Brugada syndrome, ventricular tachycardia, atherosclerosis, hypertension, restenosis, ischemic cardiovascular diseases, cardiomyopathy, cardiac fibrosis, arrhythmia, water retention, diabetes (including gestational diabetes), obesity, peripheral arterial disease, cerebrovascular accidents, transient ischemic attacks, traumatic brain injuries, amyotrophic lateral sclerosis, burn injuries (including sunburn) and preeclampsia.Type: GrantFiled: November 18, 2013Date of Patent: December 30, 2014Assignee: Novartis AGInventors: Frédéric Zecri, Kayo Yasoshima, Philipp Grosche, Jun Yuan, Hongjuan Zhao
-
Patent number: 8920778Abstract: It is an object of the present invention to provide a targeting agent, which enables the delivery of a drug to tumor sites or the imaging of tumor sites by utilizing its effect of accumulating to such tumor sites. The present invention provides a targeting agent for tumor site, which comprises a hydrophilic polymer-modified carrier coated with a gelatin-like protein that has repeats of a sequence represented by Gly-X-Y characteristic to collagen and has two or more sequences of cell adhesion signals in a single molecule wherein X and Y each independently represent an amino acid and a plurality of Gly-X-Y sequences may be the same or different.Type: GrantFiled: January 7, 2011Date of Patent: December 30, 2014Assignee: FUJIFILM CorporationInventors: Kazutaka Ogiwara, Makoto Ohno, Masayoshi Kojima, Masayuki Kawakami, Chihaya Kakinuma, Tasuku Sasaki, Kiyohito Takada
-
Patent number: 8912310Abstract: The present disclosure describes environmentally responsive polypeptides capable of displaying stimuli-triggered conformational changes in a reversible or irreversible manner that may be accompanied by aggregation. Polypeptides include a number of repeated motifs and may be elastomeric or non-elastomeric. The polypeptides may be used to deliver therapeutics to a biological site and to develop bioactive polypeptides that are environmentally responsive.Type: GrantFiled: May 29, 2013Date of Patent: December 16, 2014Assignee: Duke UniversityInventors: Ashutosh Chilkoti, Felipe Garcia Quiroz
-
Patent number: 8906853Abstract: The present invention relates to novel cyclosporine analogues having antiviral activity against HCV and useful in the treatment of HCV infections. More particularly, the invention relates to novel cyclosporine analogue compounds, compositions containing such compounds and methods for using the same, as well as processes for making such compounds.Type: GrantFiled: November 27, 2013Date of Patent: December 9, 2014Assignee: Enanta Pharmaceuticals, Inc.Inventors: Yat Sun Or, In Jong Kim, Jiang Long, Lijuan Jiang, Sheng Sean Liu, Guoqiang Wang
-
Patent number: 8901077Abstract: The invention relates to a composition comprising albumin and a therapeutic agent, particularly a gene therapy vector. The composition is useful in the treatment of glioma.Type: GrantFiled: January 23, 2012Date of Patent: December 2, 2014Assignee: Renishaw (Ireland) LimitedInventors: Edward White, Steven Streatfield Gill
-
Patent number: 8895069Abstract: The present invention relates to a drug delivery composition comprising a hyaluronic acid-peptide conjugate micelle and a production method thereof. According to the drug delivery composition and the production method of the drug-loaded, hyaluronic acid-peptide conjugate micelle of the present invention, the reaction for encapsulating can proceed in a mixed solvent of an aqueous solvent and an organic solvent. Therefore, the present invention can be applied to various types of water-insoluble active components and the biocompatible and biodegradable derivative can encapsulate a drug to provide a drug-loaded micelle, which is safe to be applied for human bodies. Moreover, the micelle has a therapeutic effect from the peptide contained therein, which can act in combination with the drug as packing therein. Therefore, the drug delivery composition and its production method can be utilized in the field of producing a sustained release formulation with an extended duration of the medicinal effect.Type: GrantFiled: December 15, 2011Date of Patent: November 25, 2014Assignee: Postech Academy-Industry FoundationInventors: Sei Kwang Hahn, Choun-Ki Joo, Yoon Keun Kim, Seung Kew Yoon, Eun Ju Oh, Ki Su Kim, Hyemin Kim, Kitae Park, Jeong-A Yang, Jun-Sub Choi, You Me Tae, Wonhee Hur
-
Patent number: 8883862Abstract: A method for locally controlled release of an effective amount of PTH(1-34) by a hyaluronic acid based hydrogel that can injected intra-articularly for the treatment of osteoarthritis is provided.Type: GrantFiled: January 12, 2012Date of Patent: November 11, 2014Assignee: Kaohsiung Medical UniversityInventors: Mei-Ling Ho, Rajalakshmanan Eswaramoorthy, Shun-Cheng Wu, Gwo-Jaw Wang, Je-Ken Chang, Yin-Chih Fu, Cherng-Chyi Tzeng, Hui-Ting Chen, Yao-Hsien Wang
-
Patent number: 8883731Abstract: An agent for reducing risk in onset of diseases ascribable to non-dipping circadian profile of blood pressure is provided. This agent is capable of effectively lowering SBP from night to early morning in individuals with non-dipping circadian profile of blood pressure, in particular, normal individuals with normal SBP and DBP among them, and is thus capable of reducing risk in onset, particularly likely in the morning, of diseases caused by circadian variation of blood pressure. The agent is intended for administration to such subjects, and contains a hydrolysate or a concentrate thereof, containing Val-Pro-Pro and Ile-Pro-Pro and obtained by hydrolysis of animal milk protein.Type: GrantFiled: March 26, 2013Date of Patent: November 11, 2014Assignee: CALPIS Co., LtdInventors: Mari Takahashi, Naoyuki Yamamoto, Kazuhisa Yamada, Toshirou Iketani
-
Patent number: 8877890Abstract: Melanocortin receptor-specific cyclic peptides of the formula where R1, R2, R3, R4, R5, R6, R7, R8 and R9 are as defined in the specification, compositions and formulations including the peptides of the foregoing formula or salts thereof, and methods of preventing, ameliorating or treating melanocortin-1 receptor-mediated or responsive diseases, indications, conditions and syndromes.Type: GrantFiled: June 5, 2013Date of Patent: November 4, 2014Assignee: Palatin Technologies, Inc.Inventors: Wei Yang, Yi-Qun Shi
-
Patent number: 8846759Abstract: The present invention relates to the use of a low-caloric high-protein nutritional composition for use in the prevention or treatment of a disease or condition in a mammal, which involves muscle decline, as well as to specific low-caloric high-protein nutritional compositions for stimulating muscle protein synthesis in a mammal.Type: GrantFiled: December 23, 2010Date of Patent: September 30, 2014Assignee: N.V. NutriciaInventors: Yvette Charlotte Luiking, George Verlaan, Marion Jourdan
-
Patent number: 8846020Abstract: Conjugates are provided herein which comprise a protein attached to at least two polymeric moieties, at least one of which exhibits reverse thermal gelation. The conjugates are suitable for being cross-linked by non-covalent and/or covalent cross-linking. Compositions-of-matter comprising cross-linked conjugates are provided herein, as well as processes for producing same. Methods of controlling a physical property of compositions-of-matter are also provided herein. The conjugates and compositions-of-matter may be used for various applications, such as cell growth, tissue formation, and treatment of disorders characterized by tissue damage or loss, as described herein.Type: GrantFiled: December 16, 2010Date of Patent: September 30, 2014Assignee: Regentis Biomaterials Ltd.Inventors: Dror Seliktar, Yonatan Shachaf
-
Patent number: 8802078Abstract: According to some embodiments, the present invention provides a modified silicone surface for interference to pathogen colonization comprising: an activated silicone layer; a plurality of cross-linking dendrimers adsorbed onto to the activated silicone layer; a plurality of ligand derivatives, each bound to at least one of the plurality of cross-linking dendrimers; and a benign biofilm adhered to the plurality of ligand derivatives. According to some embodiments, the present invention provides a method for making a modified silicone surface for interference to pathogen colonization comprising activating a silicone surface; adsorbing a plurality of cross-linking dendrimers to the silicone surface; binding a plurality of ligand derivatives to the plurality of cross-linking dendrimers; and adhering a benign biofilm to the plurality of ligand derivatives.Type: GrantFiled: March 12, 2012Date of Patent: August 12, 2014Assignee: University of HoustonInventor: Chengzhi Cai